Zentalis Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Zentalis Pharmaceuticals, Inc. reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of eleven analysts for the quarter was for a loss of 54 cents per share. Wall Street expected results to range from -63 cents to -42 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Zentalis Pharmaceuticals, Inc.'s reported EPS for the quarter was a loss of 34 cents​.

• The company reported a quarterly loss of $28.82 million.

• Zentalis Pharmaceuticals, Inc. shares had fallen by 37.9% this quarter and gained 27.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.9% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Zentalis Pharmaceuticals, Inc. is $8.00, about 78.5% above its last closing price of $1.72

This summary was machine generated from LSEG data November 9 at 10:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)